Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5560930 | 0.92 | PTGS2 (0.41) | AKR1C3AKR1C2LMNAPTGS2PTGS1 | |
| SCHEMBL5553892 | 0.91 | PTGS2 (0.41) | AKR1C3AKR1C2PTGS2PTGS1TP53 | |
| SCHEMBL5554400 | 0.91 | PTGS2 (0.44) | AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL5559355 | 0.90 | AKR1C3 (0.44) | AKR1C3AKR1C2LMNAPTGS2PTGS1 | |
| SCHEMBL5558996 | 0.90 | PTGS2 (0.46) | AKR1C3AKR1C2PTGS2PTGS1TP53 | |
| SCHEMBL6426606 | 0.90 | AKR1C3 (0.43) | AKR1C3AKR1C2LMNAPTGS2PTGS1 | |
| SCHEMBL5801325 | 0.89 | AKR1C3 (0.43) | AKR1C3AKR1C2PTGS2PTGS1TP53 | |
| SCHEMBL5801149 | 0.88 | AKR1C3 (0.43) | AKR1C3AKR1C2LMNAPTGS2PTGS1 | |
| SCHEMBL5553723 | 0.88 | PTGS2 (0.43) | AKR1C3AKR1C2PTGS2PTGS1TP53 | |
| SCHEMBL5559763 | 0.87 | AKR1C3 (0.41) | AKR1C3AKR1C2PTGS2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006050120-A2 | SYNTHESIS OF COX-2 AND FAAH INHIBITORS | MICROBIA, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050032747-A1 | COX-2 and FAAH inhibitors | POLYMER CONCEPTS TECHNOLOGIES PBY, INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032747-A1 | COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGS2 | AKR1C3 585/4885AKR1C2 342/4885LMNA 4397/4885 |
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | AKR1C3 577/4885AKR1C2 563/4885LMNA 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.